Berkshire Hathaway's Capital Machine: Buybacks, Bold Bets, and a New Global Playbook
Published on 09/01/2026 at 15:54 | Editorial boerse-global.de
When a company repurchases $4.5 billion of its own stock in a single quarter, the market tends to take notice. When that company is Berkshire Hathaway — and the buyback is the most aggressive since 2021 — the signal becomes impossible to ignore. Greg Abel, now fully in command of the conglomerate's investment decisions, has effectively told shareholders that he considers the equity cheap.
The timing is telling. Berkshire's shares have slipped roughly 2.1 percent since the second-quarter earnings report landed about a month ago, even as the underlying numbers painted a picture of robust health. Revenue climbed 10.0 percent to $101.81 billion, operating earnings advanced 16.3 percent to $12.98 billion, and net income reached $25.67 billion — buoyed by a $12.68 billion after-tax gain in the equity portfolio. The buyback announcement, then, arrives as a vote of confidence during a moment of mild market skepticism.
A Portfolio in Active Motion
The repurchase program marks the first meaningful return to buybacks since early 2024, and it lands squarely in the opening chapter of Abel's solo stewardship. With portfolio managers Todd Combs and Ted Weschler having departed at the end of last fiscal year, Abel now wields sole authority over the company's roughly $299 billion US equity portfolio. The message embedded in the buyback is straightforward: management regards its own shares as a compelling use of capital.
That conviction extends to other corners of the portfolio, where Abel has been anything but passive. Regulatory filings recently revealed that Berkshire holds 28.88 million shares of DaVita, the dialysis provider — a 45.27 percent stake valued at approximately $6.43 billion. That position ranks as the conglomerate's eleventh-largest holding and underscores a concentrated approach that favors deep conviction over broad diversification.
The DaVita stake is part of a broader pattern of consolidation. Berkshire expanded its Alphabet position by 83 percent during the second quarter to roughly 106 million shares, elevating the tech giant to the portfolio's third-largest holding. At the same time, Abel demonstrated a willingness to exit entirely when conviction fades: the company liquidated its position in Constellation Brands and sharply trimmed stakes in Capital One Financial and Kroger.
Should investors sell immediately? Or is it worth buying Berkshire Hathaway?
Perhaps the most striking reversal, however, is in airlines. Berkshire built its Delta Air Lines position by 44 percent to 57.3 million shares, worth around $5.4 billion — a remarkable pivot given Warren Buffett's complete exit from the sector in 2020. The move suggests Abel is willing to revisit industries his predecessor had written off.
Beyond Equities: Alliances and Acquisitions
The portfolio shifts tell only part of the story. In March, Berkshire's insurance subsidiary National Indemnity forged a capital alliance with Japan's Tokio Marine, a partnership that has strengthened the Japanese insurer's ability to pursue cross-border acquisitions. For Berkshire, the arrangement represents a less conspicuous but strategically significant avenue for international expansion within its insurance operations.
That deal fits into a larger industrial narrative. In August, Berkshire completed the $9.7 billion acquisition of OxyChem from Occidental Petroleum — a transaction negotiated under Buffett but finalized under Abel's leadership. Taken together, the DaVita position, the Tokio Marine alliance, and the OxyChem closing depict a conglomerate that is simultaneously consolidating existing holdings and forging new industrial and international connections.
The Benchmark Effect
Berkshire's capital allocation model continues to reverberate well beyond its own shareholder base. On Monday, KKR & Co. announced the sale of USI Insurance Services to Aon for $17 billion, explicitly citing the ambition to emulate Berkshire's "strategic holdings" approach for long-term equity returns. The Omaha-based conglomerate, it seems, remains the industry's reference point for capital discipline.
That reputation persists even as questions surface about the transition ahead. Morningstar assigned Berkshire a "narrow" economic moat with "low" uncertainty in mid-August, while cautioning that investment returns could soften as Abel assumes full control of the portfolio. Automated valuation models, such as the one run by Simply Wall St, currently flag the stock as undervalued based on a price-to-earnings ratio of 12.6 — though such screeners carry obvious methodological limitations.
A Side Note in the Margins
One curiosity deserves mention: former President Donald Trump disclosed in June that he had purchased Berkshire Hathaway shares while simultaneously shedding other technology holdings. The disclosure generated considerable media attention, though its operational significance for the conglomerate is minimal. It functions more as a footnote to a narrative dominated by Abel's strategic direction — the DaVita position, the Tokio Marine alliance, the OxyChem deal, and now the return of meaningful buybacks.
With the market capitalization hovering near $1.1 trillion and B-shares trading about 6 percent below their 52-week high of $537.74, Berkshire finds itself in a curious position: not at record levels, but hardly at a discount either. The buyback program suggests Abel sees value where the market sees uncertainty. Given the breadth of activity across the portfolio, his conviction may be the more reliable signal.
Ad
Berkshire Hathaway Stock: New Analysis - 1 September
Fresh Berkshire Hathaway information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
